1. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans;Boldf;Cancer Research.,1988
2. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2;Christiansen;Am. J. Med.,1988
3. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells;Denicoff;Ann. Int. Med.,1987
4. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells;Gemlo;Cancer Res.,1988
5. Phase II trial of interleukin-2 bolus priming followed by continuous infusion with lymphokine activated killer cells (IL-2/LAK) in metastatic melanoma;Rayner;Am. Soc. Clin. Oncol.,1988